TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03084159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education worksheet
Description: Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
Study: NCT03886324

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GIE Medical Drug Coated Balloon
Description: Stricture patients treated by DCB
Study: NCT02477865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168(100µg)
Description: 100µg,Subcutaneous injection,once a week. continued for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168(200µg)
Description: 200µg,Subcutaneous injection,once a week. continued for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
Study: NCT02232438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation therapy
Description: Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).
Study: NCT03949777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aer-O-Scope Colonoscopy
Description: resection or biopsy of colonic abnormalities for histopathalogical evaluation
Study: NCT00349076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU and oxaliplatin
Description: Preoperative radiochemotherapy:~Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35~Adjuvant Chemotherapy:~Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: Preoperative radiochemotherapy:~5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d~Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles
Study: NCT06485180

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Participants from conservative group were selected as uterine curettage (D\&C) cohort , hysteroscopy cohort, Uterine Artery Embolization (UAE) in Combination with D\&C, without MTX cohort, UAE in Combination D\&C with MTX cohort and UAE+ D\&C+hysteroscopy.~Participants from CSP excision plus hysterotomy closure group were selected as transvaginal CSP excision cohort, hysteroscopy-assisted laparoscopic CSP excision cohort and abdominal CSP excision cohort.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Participants from conservative group were selected as uterine curettage (D\&C) cohort , hysteroscopy cohort, Uterine Artery Embolization (UAE) in Combination with D\&C, without MTX cohort, UAE in Combination D\&C with MTX cohort and UAE+ D\&C+hysteroscopy.~Participants from CSP excision plus hysterotomy closure group were selected as transvaginal CSP excision cohort, hysteroscopy-assisted laparoscopic CSP excision cohort and abdominal CSP excision cohort.
Study: NCT01972178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRC-4016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins
Description: Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statins
Description: Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
Study: NCT02617290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor Loading dose of 180mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 90mg bid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel Loading dose of 300 or 600mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 75mg per day.
Study: NCT04011644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-CHESS clinically-integrated
Description: Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a health coach. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
Study: NCT03255447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunoadsorption
Description: Fresenius Globaffin
Study: NCT04956250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traffic Calming Curbs
Description: Temporary curb extensions, placed at intersections.
Study: NCT03341468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urethral catheter immobilization
Description: Subjects assigned to the control group will undergo radical prostatectomy with placement and securing of the urethral catheter per the standard of care. The catheter will be secured to the leg using cloth tape. Subjects will also be given an elastic leg strap that they may use following discharge, as is routine. Subjects will attend routine follow up appointments with their surgeon for removal of the urethral catheter and void trial.~Subjects will be asked to fill out a symptom-based questionnaire prior to leaving the office. This will conclude their participation in the study.
Study: NCT01743027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-4943A ophthalmic solution
Study: NCT04249635

Intervention type: DIETARY_SUPPLEMENT
Intervention: DHA
Description: Women received supplementation of Based on Schizochytrium oil, 100% DHA (DSM) from 14 weeks of pregnancy until delivery.

Intervention type: DIETARY_SUPPLEMENT
Intervention: DHA
Description: Women received supplementation of Based on Schizochytrium oil, 100% DHA (DSM) from 14 weeks of pregnancy until delivery.
Study: NCT00363467

Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.~Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously.

Intervention type: DRUG
Group type: OTHER
Intervention: Leukapheresis
Description: leukapheresis
Study: NCT01743027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.2%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.1%
Study: NCT00363467

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stem cell reinfusion
Description: autologous stem cell transplant
Study: NCT01272778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Oral capsule, 0.2 mg, single acute dose
Study: NCT01743027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-4943A ophthalmic solution vehicle
Study: NCT01272778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: oral capsule, 0.5 mg, single acute dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: oral capsule, 1.0 mg, single acute dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: oral capsule, 2.0 mg, single acute dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule, single acute dose
Study: NCT04956250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-Street Pedestrian Sign
Description: Yield sign placed in middle of road at intersection.
Study: NCT03391011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BBL Experimental Navigation System
Description: Comparison of accuracy of screw placement using experimental system while monitored by clinically approved system.
Study: NCT01753518

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular suture
Description: subcuticular Monocryl suture closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular staple
Description: subcuticular staple wound closure with INSORB 20 device
Study: NCT00142103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG10101
Description: CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG10101
Description: CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG10101
Description: CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG10101
Description: CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPG10101
Description: CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
Study: NCT01899989

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin or carboplatin-based
Description: Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
Study: NCT00470704

Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib

Intervention type: DRUG
Group type: OTHER
Intervention: Lapatinib

Intervention type: DRUG
Group type: OTHER
Intervention: Herceptin

Intervention type: DRUG
Group type: OTHER
Intervention: Herceptin
Study: NCT03522142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB081776
Description: INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB081776
Description: INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
Study: NCT03399500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Case Management at Homeless Recovery Program
Description: In-Person Case Management at Homeless Recovery Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-Person Case Management at Homeless Recovery Program
Description: In-Person Case Management at Homeless Recovery Program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Case Management at Homeless Recovery Program
Description: In-Person Case Management at Homeless Recovery Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unlimited Smartphone
Description: Smartphone with unlimited calls, texts, and data plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unlimited Smartphone
Description: Smartphone with unlimited calls, texts, and data plan

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Based Case Management (SPCM) app
Description: Smartphone Based Case Management app
Study: NCT02106949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMS contact with patient after discharge in intervention group
Study: NCT02661373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJ733
Description: SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single, multi, or boosted oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Commercially available cobicistat 150 mg tablets will be used. It will be administered as a single oral dose together with SJ733.
Study: NCT03418480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT113
Description: Intradermal vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT113
Description: Intradermal vaccine
Study: NCT03626038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A.L.P.S. Proximal Humerus Plating System
Description: Anatomically contoured, locking plates that can be customized intra-operatively, multidirectional screws allow for stable fixation for a wide variety of patients.
Study: NCT04876560

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Application of CDSS to provide nutritional care in breast cancer patients from home
Description: A personalised dietary plan was implemented by the CDSS. The CDSS estimated body mass index (BMI) and Total daily Energy Expenditure (TEE) according to individual's incorporated data. For overweight and obese patients, the CDSS produced a hypocaloric diet, in which daily energy intake was less than TEE by approximately -500 kcal/day. Nutrient distribution was in line with the Mediterranean dietary pattern. Patients received individual login passwords to CDSS allowing access to their personal profile from home. During the trial, patients were instructed to record food diaries in the CDSS every week, which were also made available to the dieticians. Visiting the CDSS, patients had the opportunity to track their progress e.g. monitoring goals of body weight, physical activity, consumption of fruits, vegetables, legumes.

Intervention type: OTHER
Group type: OTHER
Intervention: General lifestyle advice to breast cancer patients by phone
Description: General lifestyle guidelines were provided by phone and food diaries were sent via emails.
Study: NCT03677128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mNavigator
Description: Allied health providers at BMC will use mNavigator to facilitate compliance with protocol-driven treatment and reduce patient abandonment for patients diagnosed with Burkitt lymphoma, Diffuse large B-cell lymphoma or retinoblastoma.
Study: NCT02313480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage
Description: Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: massage
Description: Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning
Study: NCT01101724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mandated Rest, Intervention
Description: In addition to CDC based discharge instructions, the intervention group will receive instructions with strict activity restriction explicitly stating No return to school and No Physical Activity for the next five days. Patients and parents in the intervention group will be provided school and work excuses for the five days post-injury.
Study: NCT02609893

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: modified directly observed therapy (mDOT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: unobserved dosing
Study: NCT04145622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan (I-DXd)
Description: A total anti-B7H3 antibody and MAAA-1181a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifinatamab deruxtecan (I-DXd)
Description: A total anti-B7H3 antibody and MAAA-1181a
Study: NCT01956084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (Group A)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMP1/2 CTLs (Group B)
Description: Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:~Dose Level One:~Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2~Dose Level Two:~Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2~Dose Level Three:~Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2
Study: NCT01065740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient education
Study: NCT00792753

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Endeavor Coronary Stent System
Description: coronary stent implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DESyne BD Novolimus Stent System
Description: coronary stent implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DESyne Novolimus Stent System
Description: coronary stent implantation
Study: NCT01154712

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real Deep TMS
Description: Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Deep TMS
Description: Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
Study: NCT03865563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retrograde venous infusion of gemcitabine/lipiodol
Description: Access will be gained into the portal vein via a transhepatic approach. The pancreatic tumor-draining veins will be accessed via a catheter positioned in the portal vein, superior mesenteric vein or splenic vein. The catheter is then advanced into the vein draining the segment in which the targeted tumor is located. Tumor location and its venous drainage will be confirmed with sub-selective pancreatic venography and cone-beam CT. Once correct catheter positioning is confirmed, the gemcitabine/Lipiodol® emulsion will be administered under real-time fluoroscopic guidance until the entire dose is administered or until stasis is achieved in the vein through which the drug is being delivered.
Study: NCT00852163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine with Busulfan
Description: Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
Study: NCT03835286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 6 grams of Vitamin C in 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos: 250 ml of 0.9% saline in continuous infusion for 24 hours, 3 doses.
Study: NCT04204395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peanut Ball
Description: The participants in the experimental group will use the peanut ball at least every 2 hours, 30-minute usage for each time. More frequency will be available. Then, the participants will stop using the peanut ball when cervical os is dilated and effaced, may be ready to push.
Study: NCT00830024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam Extended-Release 3 mg Tablets
Description: 1 x 3 mg, single dose non-fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam Extended-Release 3 mg Tablets
Description: 1 x 3 mg, single dose non-fasting
Study: NCT03914365

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided pudendal nerve block (PNB) and Ultrasound-guided penile nerve block (DPNB)
Description: Our primary objective is to compare analgesia between the two blocks during and after pediatric circumcisions to minimize post-operative pain.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided pudendal nerve block (PNB) and Ultrasound-guided penile nerve block (DPNB)
Description: Our primary objective is to compare analgesia between the two blocks during and after pediatric circumcisions to minimize post-operative pain.
Study: NCT01121588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
Study: NCT03754465

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-DFU
Description: Application of ALLO-ASC-DFU Sheet to diabetic foot ulcer

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogel SHEET(Vehicle control)
Description: Application of Hydrogel SHEET to diabetic foot ulcer
Study: NCT01334242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Schedule A
Description: Dosing 1 hour before breakfast
Study: NCT02985281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir Oral Product
Description: direct acting antiviral drug for HCV infection
Study: NCT02546687

Intervention type: OTHER
Intervention: Venous blood sampling
Description: The investigators will take 1-2 cc of venous blood from proximal part of stomach before gastric tube creation and in the same time the investigators will take same amount of venous blood from peripheral vein. This blood will be analyzed in the ABL800 FLEX blood gas analyzer as a routine blood analyses that making by anesthesiologist during the operation. This blood sampling the investigators will make again after 15-30 minutes from the same area in proximal stomach (after creation of gastric tube) and peripheral vein just before anastomosis creation. The investigators will measure components of venous blood gases (O2, pH, CO2, lactate) from the area of future anastomosis before construction of gastric tube and just before creation of anastomosis ( after 15-30 minutes), compare the results of this analysis with systemic venous blood.